Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood.2020006442 http://scihub22266oqcxt.onion/10.1182/blood.2020006442 32463890!7256362!32463890     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32463890.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2020 ; 135 (22): 1925-1926 Nephropedia Template TP {{tp|p=32463890|t=2020. COVID-19 and SCA: an old friend comes to the rescue |pdf=|usr=}}{{32463890}} gab.com Text COVID-19 and SCA: an old friend comes to the rescue JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=32463890 #FOAvip In this issue of Blood, DeBaun proposes a forward-thinking evidence-based strategy to limit the impact of the SARS-CoV-2 coronavirus disease (COVID-19) pandemic on children with sickle cell anemia (SCA) at high risk for stroke. DeBaun argues that rapid initiation of low- and fixed-dose (10 mg/kg per day) hydroxyurea treatment while the children are receiving prophylactic chronic transfusions, and before blood supply is disrupted, ensures that when blood shortages do occur, the clinical benefit of hydroxyurea will be more quickly established, and the children will be better protected. Twit Text FOAVip COVID-19 and SCA: an old friend comes to the rescue ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=32463890 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32463890 #FOAvip English Wikipedia <ref>{{Cite pmid|32463890}}</ref> COVID-19 and SCA: an old friend comes to the rescue #MMPMID32463890 Novelli EM Blood 2020[May]; 135 (22): 1925-1926 PMID32463890show ga In this issue of Blood, DeBaun proposes a forward-thinking evidence-based strategy to limit the impact of the SARS-CoV-2 coronavirus disease (COVID-19) pandemic on children with sickle cell anemia (SCA) at high risk for stroke. DeBaun argues that rapid initiation of low- and fixed-dose (10 mg/kg per day) hydroxyurea treatment while the children are receiving prophylactic chronic transfusions, and before blood supply is disrupted, ensures that when blood shortages do occur, the clinical benefit of hydroxyurea will be more quickly established, and the children will be better protected. |*Hydroxyurea[MESH] |*Stroke[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Child[MESH] |Coronavirus Infections[MESH] |Friends[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral[MESH]COVID-19 and SCA: an old friend comes to the rescue (epmc).pdf DeepDyve Pubget Overpricing